# Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02220907` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02220907](<https://clinicaltrials.gov/study/NCT02220907>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02220907

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

## Technical summary

Registry record NCT02220907. Allocation not applicable; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-08-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 153 participants (enrolled count; ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Start date: 2014-08 (registry gives no type) (ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Results first posted: 2018-08-16 (ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02220907, source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02220907-2026-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Teneligliptin/Canagliflozin
- Lead sponsor: Tanabe Pharma Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Tanabe Pharma Corporation (`cardio:org-tanabe-pharma-corporation`)

## Provenance

Content hash: d43f952347821b4f449e5da60e826ec0b70c22a1cadb29cd5c1e1d7c1ac6de95
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
